H-Index
75
Scimago Lab
powered by Scopus
JCR
Clarivate
Analytics
18%
Acceptance
Rate
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST

Logo



eISSN: 1643-3750

Get your full text copy in PDF

Susceptibility of Klebsiella spp. to tigecycline and other selected antibiotics

Alicja Sekowska, Eugenia Gospodarek

Med Sci Monit 2010; 16(6): BR193-196

ID: 880608


Background:    Tigecycline is a new glycylcycline with broad-spectrum activity. Among these new agents, tigecycyline is unique in generally having good activity against Gram-negative bacteria. Tigecycline has been approved for the treatment of complicated intra-abdominal infections and complicated skin and skin structure infections. Tigecycline had good activity against most ESBL-producing Enterobacteriaceae and may be a therapeutic alternative to carbapenems in some infections caused by ESBL-producing isolates, many of which are also multiresistant to quinolones, aminoglycosides, and classical tetracyclines.
    Material/Methods:    One hundred and eight clinical isolates of Klebsiella spp. (64 K. pneumoniae and 44 K. oxytoca) were included. The susceptibility to selected antibiotics was tested by the disk-diffusion method. Tigecycline’s MIC was determined by the Etest.
    Results:    Of all the analyzed Klebsiella spp. strains, 31 (28.7%) produced ESBLs. Most of the Klebsiella spp. strains were susceptible to imipenem (100%), tigecycline (92.5%), and the combination of piperacilline and tazobactam (80.6%). Tigecycline exhibited high activity against Klebsiella strains, with MICs ranging from 0.19 to 4 microg/ml.
    Conclusions:    Tigecycline demonstrated excellent inhibitory activity against the analyzed strains. These data suggest that tigecycline, with an expanded broad-spectrum antimicrobial activity, may be an effective therapeutic option for the treatment of serious infections caused by Klebsiella strains.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree